Share This Page
Suppliers and packagers for TRIJARDY XR
✉ Email this page to a colleague
TRIJARDY XR
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0380-13 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-13) | 2020-04-23 |
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0380-68 | 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-68) | 2020-04-23 |
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0385-77 | 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-77) | 2020-04-23 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Trijardy XR
Introduction
Trijardy XR is an innovative prescription medication designed for the management of type 2 diabetes mellitus. Created as a fixed-dose combination, it integrates three active ingredients—empagliflozin, linagliptin, and metformin—aimed at optimizing glycemic control through complementary mechanisms. The drug’s complexity in formulation and manufacturing demands a robust supply chain comprising multiple specialized suppliers. This article critically examines the key suppliers involved in the production of Trijardy XR, evaluating their roles, manufacturing capabilities, and strategic importance for stakeholders.
Understanding Trijardy XR’s Composition and Manufacturing
Active Pharmaceutical Ingredients (APIs):
- Empagliflozin: An SGLT2 inhibitor, primarily sourced from suppliers specializing in diabetes-related APIs.
- Linagliptin: A DPP-4 inhibitor, with manufacturing concentrated among a handful of global API producers.
- Metformin: A widely used biguanide, typically produced by large pharmaceutical API suppliers with extensive manufacturing capacity.
Formulation and Final Dosage Form:
The unique extended-release (XR) formulation of Trijardy XR necessitates specialized excipients and manufacturing processes, often handled by contract manufacturing organizations (CMOs) with expertise in controlled-release formulations.
Primary API Suppliers for Trijardy XR
Empagliflozin Suppliers
Empagliflozin’s API is sourced from several key producers, notably:
- Boehringer Ingelheim: The original developer of empagliflozin, also a manufacturer providing APIs to licensed partner companies. Their manufacturing facilities in Germany and the US are ISO-certified, ensuring high-quality standards.
- Luye Pharma: Based in China, Luye has become a significant supplier, leveraging cost-effective manufacturing capabilities aligned with global quality standards.
- Sun Pharmaceutical Industries: An Indian pharmaceutical giant, producing empagliflozin APIs at scale for international markets.
Linagliptin Suppliers
Linagliptin is predominantly supplied by:
- Boehringer Ingelheim: Maintains a dominant position in the production of linagliptin APIs, leveraging proprietary manufacturing processes that meet stringent quality controls.
- Luye Pharma: As with empagliflozin, Luye supplies linagliptin APIs, often catering to lower-cost markets.
- Zhejiang Huahai Pharmaceutical: A Chinese-based manufacturer with approved APIs for global export, including linagliptin.
Metformin Suppliers
Given its maturity, metformin's API involves a broader supply base:
- Novartis: Produces high-purity metformin APIs compliant with international standards.
- Hygienic Laboratories: An Indian manufacturer that supplies metformin APIs worldwide.
- APICCO: A Chinese producer with extensive manufacturing capacity.
Excipient and Formulation Suppliers
The XR formulation's stability and bioavailability rely on high-quality excipients:
- BASF and Dow Chemical: Major suppliers of pharmaceutical-grade excipients, including release-controlling agents and binders compatible with extended-release formulations.
- CordenPharma: Specializes in controlled-release excipients and customized drug delivery solutions.
- CMO Partners: Several established CMOs, such as Catalent and Patheon, handle the formulation and tablet manufacturing.
Supply Chain Dynamics and Strategic Considerations
Geographical Diversification
To mitigate risks associated with geopolitical, regulatory, or pandemic-related disruptions, pharmaceutical companies often diversify their supplier base across regions.
- China and India: Major suppliers of APIs due to cost efficiencies. However, recent geopolitical tensions and supply chain security concerns have prompted efforts to diversify sourcing.
- Europe and North America: Suppliers like Boehringer Ingelheim and Novartis ensure supply continuity and regulatory compliance, albeit at higher costs.
Regulatory Certification
Suppliers must meet rigorous regulatory standards (e.g., cGMP, ISO certification) to qualify for supplying APIs and excipients for US and European markets. This compliance impacts supplier selection and long-term partnerships.
Manufacturing Capacity and Scalability
Considering the demand for Trijardy XR, capacity planning plays a crucial role, with leading API producers investing heavily in expanding production capabilities. Strategic partnerships with CMOs allow for scalable manufacturing of the final dosage forms, ensuring consistent supply.
Implications for Stakeholders
Pharmaceutical Companies:
Critical to maintain diversified supplier relationships to safeguard against shortages and compliance issues. Strategic sourcing from high-quality, compliant manufacturers ensures product integrity.
Investors and Business Analysts:
Monitoring supplier capacity expansions and geopolitical risks informs risk assessments and investment decisions. Companies with resilient supply chains are better positioned to capitalize on market demand.
Healthcare Providers and Patients:
Reliable supplier networks directly influence drug availability and affordability, impacting treatment continuity and patient outcomes.
Conclusion
The supply landscape for Trijardy XR involves a complex, multi-tiered network of global API and excipient manufacturers. Diversification across regions such as China, India, and Europe, complemented by rigorous regulatory compliance, is pivotal to ensuring reliable production. Strategic partnerships with CMOs further optimize formulation and manufacturing efficiencies. As the demand for innovative diabetes treatments like Trijardy XR continues to grow, securing a resilient supply chain remains a paramount focus for all stakeholders.
Key Takeaways
- Diverse API sourcing from established global manufacturers (e.g., Boehringer Ingelheim, Luye Pharma, Novartis) minimizes supply risks.
- Regulatory compliance with cGMP and ISO standards is critical for qualifying suppliers.
- Geographical diversification between China, India, and Western countries enhances supply resilience amid geopolitical uncertainties.
- CMO partnerships facilitate high-quality formulation and scalable manufacturing of Trijardy XR.
- Ongoing capacity expansion by suppliers indicates robust future supply potential aligned with market growth.
FAQs
1. Who are the primary API suppliers for empagliflozin used in Trijardy XR?
The main suppliers include Boehringer Ingelheim, Luye Pharma, and Sun Pharmaceutical Industries, all providing high-quality empagliflozin APIs globally.
2. How does supplier diversification impact the availability of Trijardy XR?
Diversification reduces dependency on single sources, mitigating risks from regional disruptions, regulatory delays, or supply shortages, thus ensuring consistent drug availability.
3. What regulatory standards must suppliers meet to provide APIs for Trijardy XR?
Suppliers must comply with current Good Manufacturing Practices (cGMP), ISO certifications, and other international standards to meet regulatory requirements for US and European markets.
4. Are there concerns about the reliance on Chinese and Indian suppliers?
While cost-effective, reliance on Chinese and Indian API manufacturers raises concerns about geopolitical stability and regulatory oversight, prompting some companies to seek diversification or local manufacturing solutions.
5. How does the formulation process influence supplier selection for Trijardy XR?
Formulation of XR tablets requires expertise in controlled-release technology. Trusted CMOs with capabilities in advanced formulation ensure quality, stability, and scalability of the final product.
Sources:
- [1] U.S. Food and Drug Administration (FDA). "Supply Chain and Manufacturing" – [FDA website].
- [2] Boehringer Ingelheim. "Product Quality Standards" – [Company website].
- [3] Luye Pharma Annual Report. "API Manufacturing Capabilities" – Luye Pharma.
- [4] Novartis. "API manufacturing and quality assurance" – Novartis Reports.
- [5] CordenPharma. "Controlled Release Excipients" – Corporate Brochure.
More… ↓
